Press Release

BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

December 20, 2022

PR - BLRX announces AGI-134 results (Hebrew) (final).pdf 241 KB

Press Releases View all

March 22, 2023

BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates

March 15, 2023

BioLineRx to Report 2022 Annual Financial Results on March 22, 2023

March 6, 2023

BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Upcoming Events View all